The role of gut microbiota and metabolomic pathways in modulating the efficacy of SSRIs for major depressive disorder
Abstract This study aims to explore the mechanism by which gut microbiota influences the antidepressant effects of serotonin reuptake inhibitors (SSRIs) through metabolic pathways. A total of 126 patients were analyzed for their gut microbiota and metabolomics. Patients received SSRI treatment and w...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2024-12-01
|
| Series: | Translational Psychiatry |
| Online Access: | https://doi.org/10.1038/s41398-024-03208-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846112137741598720 |
|---|---|
| author | Ying Jiang Yucai Qu Lingyi Shi Mengmeng Ou Zhiqiang Du Zhenhe Zhou Hongliang Zhou Haohao Zhu |
| author_facet | Ying Jiang Yucai Qu Lingyi Shi Mengmeng Ou Zhiqiang Du Zhenhe Zhou Hongliang Zhou Haohao Zhu |
| author_sort | Ying Jiang |
| collection | DOAJ |
| description | Abstract This study aims to explore the mechanism by which gut microbiota influences the antidepressant effects of serotonin reuptake inhibitors (SSRIs) through metabolic pathways. A total of 126 patients were analyzed for their gut microbiota and metabolomics. Patients received SSRI treatment and were categorized into responder and non-responder groups based on changes in their Hamilton Depression Rating Scale (HAMD-17) scores before and after treatment. The association between gut microbiota composition and the efficacy of SSRIs was investigated through 16S rRNA gene sequencing and metabolomic analysis, and a predictive model was developed. As a result, the study found significant differences in gut microbiota composition between the responder and resistant groups. Specific taxa, such as Ruminococcus, Bifidobacterium, and Faecalibacterium, were more abundant in the responder group. Functional analysis revealed upregulation of acetate degradation and neurotransmitter synthesis pathways in the responder group. The machine learning model indicated that gut microbiota and metabolites are potential biomarkers for predicting SSRIs efficacy. In conclusion, gut microbiota influences the antidepressant effects of SSRIs through metabolic pathways. The diversity and function of gut microbiota can serve as biomarkers for predicting the treatment response, providing new insights for personalized treatment. |
| format | Article |
| id | doaj-art-b55552e3b76a419fac30346cd5b8a94c |
| institution | Kabale University |
| issn | 2158-3188 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Nature Publishing Group |
| record_format | Article |
| series | Translational Psychiatry |
| spelling | doaj-art-b55552e3b76a419fac30346cd5b8a94c2024-12-22T12:49:29ZengNature Publishing GroupTranslational Psychiatry2158-31882024-12-0114111110.1038/s41398-024-03208-zThe role of gut microbiota and metabolomic pathways in modulating the efficacy of SSRIs for major depressive disorderYing Jiang0Yucai Qu1Lingyi Shi2Mengmeng Ou3Zhiqiang Du4Zhenhe Zhou5Hongliang Zhou6Haohao Zhu7Affiliated Mental Health Center of Jiangnan UniversityAffiliated Mental Health Center of Jiangnan UniversityAffiliated Mental Health Center of Jiangnan UniversityAffiliated Mental Health Center of Jiangnan UniversityAffiliated Mental Health Center of Jiangnan UniversityAffiliated Mental Health Center of Jiangnan UniversityDepartment of Psychology, The Affiliated Hospital of Jiangnan UniversityAffiliated Mental Health Center of Jiangnan UniversityAbstract This study aims to explore the mechanism by which gut microbiota influences the antidepressant effects of serotonin reuptake inhibitors (SSRIs) through metabolic pathways. A total of 126 patients were analyzed for their gut microbiota and metabolomics. Patients received SSRI treatment and were categorized into responder and non-responder groups based on changes in their Hamilton Depression Rating Scale (HAMD-17) scores before and after treatment. The association between gut microbiota composition and the efficacy of SSRIs was investigated through 16S rRNA gene sequencing and metabolomic analysis, and a predictive model was developed. As a result, the study found significant differences in gut microbiota composition between the responder and resistant groups. Specific taxa, such as Ruminococcus, Bifidobacterium, and Faecalibacterium, were more abundant in the responder group. Functional analysis revealed upregulation of acetate degradation and neurotransmitter synthesis pathways in the responder group. The machine learning model indicated that gut microbiota and metabolites are potential biomarkers for predicting SSRIs efficacy. In conclusion, gut microbiota influences the antidepressant effects of SSRIs through metabolic pathways. The diversity and function of gut microbiota can serve as biomarkers for predicting the treatment response, providing new insights for personalized treatment.https://doi.org/10.1038/s41398-024-03208-z |
| spellingShingle | Ying Jiang Yucai Qu Lingyi Shi Mengmeng Ou Zhiqiang Du Zhenhe Zhou Hongliang Zhou Haohao Zhu The role of gut microbiota and metabolomic pathways in modulating the efficacy of SSRIs for major depressive disorder Translational Psychiatry |
| title | The role of gut microbiota and metabolomic pathways in modulating the efficacy of SSRIs for major depressive disorder |
| title_full | The role of gut microbiota and metabolomic pathways in modulating the efficacy of SSRIs for major depressive disorder |
| title_fullStr | The role of gut microbiota and metabolomic pathways in modulating the efficacy of SSRIs for major depressive disorder |
| title_full_unstemmed | The role of gut microbiota and metabolomic pathways in modulating the efficacy of SSRIs for major depressive disorder |
| title_short | The role of gut microbiota and metabolomic pathways in modulating the efficacy of SSRIs for major depressive disorder |
| title_sort | role of gut microbiota and metabolomic pathways in modulating the efficacy of ssris for major depressive disorder |
| url | https://doi.org/10.1038/s41398-024-03208-z |
| work_keys_str_mv | AT yingjiang theroleofgutmicrobiotaandmetabolomicpathwaysinmodulatingtheefficacyofssrisformajordepressivedisorder AT yucaiqu theroleofgutmicrobiotaandmetabolomicpathwaysinmodulatingtheefficacyofssrisformajordepressivedisorder AT lingyishi theroleofgutmicrobiotaandmetabolomicpathwaysinmodulatingtheefficacyofssrisformajordepressivedisorder AT mengmengou theroleofgutmicrobiotaandmetabolomicpathwaysinmodulatingtheefficacyofssrisformajordepressivedisorder AT zhiqiangdu theroleofgutmicrobiotaandmetabolomicpathwaysinmodulatingtheefficacyofssrisformajordepressivedisorder AT zhenhezhou theroleofgutmicrobiotaandmetabolomicpathwaysinmodulatingtheefficacyofssrisformajordepressivedisorder AT hongliangzhou theroleofgutmicrobiotaandmetabolomicpathwaysinmodulatingtheefficacyofssrisformajordepressivedisorder AT haohaozhu theroleofgutmicrobiotaandmetabolomicpathwaysinmodulatingtheefficacyofssrisformajordepressivedisorder AT yingjiang roleofgutmicrobiotaandmetabolomicpathwaysinmodulatingtheefficacyofssrisformajordepressivedisorder AT yucaiqu roleofgutmicrobiotaandmetabolomicpathwaysinmodulatingtheefficacyofssrisformajordepressivedisorder AT lingyishi roleofgutmicrobiotaandmetabolomicpathwaysinmodulatingtheefficacyofssrisformajordepressivedisorder AT mengmengou roleofgutmicrobiotaandmetabolomicpathwaysinmodulatingtheefficacyofssrisformajordepressivedisorder AT zhiqiangdu roleofgutmicrobiotaandmetabolomicpathwaysinmodulatingtheefficacyofssrisformajordepressivedisorder AT zhenhezhou roleofgutmicrobiotaandmetabolomicpathwaysinmodulatingtheefficacyofssrisformajordepressivedisorder AT hongliangzhou roleofgutmicrobiotaandmetabolomicpathwaysinmodulatingtheefficacyofssrisformajordepressivedisorder AT haohaozhu roleofgutmicrobiotaandmetabolomicpathwaysinmodulatingtheefficacyofssrisformajordepressivedisorder |